There are 2867 resources available
742P - First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies
Presenter: John Powderly
Session: Poster session 13
743P - A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer
Presenter: Wilson Miller
Session: Poster session 13
744P - Safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of adebrelimab: A phase I trial
Presenter: Xichun Hu
Session: Poster session 13
745P - Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody
Presenter: Kristoffer Rohrberg
Session: Poster session 13
746P - Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model
Presenter: Christian Sebesta
Session: Poster session 13
747P - Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors
Presenter: Gerald Falchook
Session: Poster session 13
748P - Development of a CCR8 monoclonal antibody for the treatment of cancer
Presenter: Guohuang Fan
Session: Poster session 13
749P - ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study
Presenter: Heinz Läubli
Session: Poster session 13
750P - Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours
Presenter: Lillian Siu
Session: Poster session 13
751P - Preclinical evaluation of SG-3-06686, a positive allosteric modulator of CXCR3
Presenter: Helena Kiefel
Session: Poster session 13